论文部分内容阅读
介绍新一代噻唑烷2,4二酮类治疗Ⅱ型糖尿病的第一个新药曲格列酮。着重对曲格列酮的药效学、临床治疗以及毒副作用等方面作简要综述。曲格列酮对非胰岛素依赖性糖尿病具有独特的药效,该药可提高胰岛素的作用,不刺激胰岛素分泌,降低血糖,但不引起低血糖,不增加体重。特异体质的患者服用曲格列酮会引起肝脏毒副作用,但目前尚不能认为易感亚群患者服用曲格列酮能引起肝脏毒副作用。曲格列酮是一个治疗非胰岛素依赖性糖尿病的新型胰岛素增敏剂,值得对其在非胰岛素依赖性糖尿病的治疗方面进一步进行临床研究,以便推广应用。
Introduction of a new generation of thiazolidine 2,4 dione treatment of type 2 diabetes, the first new drug troglitazone. It focuses on the pharmacodynamics, clinical treatment and side effects of troglitazone. Troglitazone has a unique pharmacological effect on non-insulin-dependent diabetes mellitus, which increases insulin’s activity without stimulating insulin secretion and lowering blood glucose, but does not cause hypoglycemia and does not increase body weight. Patients with specific constitutional administration of troglitazone cause side effects of the liver, but it is not yet believed that the use of troglitazone in patients with susceptible subgroups causes side effects in the liver. Troglitazone, a novel insulin sensitizer for the treatment of non-insulin-dependent diabetes mellitus, deserves further clinical study in the treatment of non-insulin-dependent diabetes mellitus for its promotion.